Author:
Lamarca Angela,Palmer Daniel H,Wasan Harpreet Singh,Ross Paul J,Ma Yuk Ting,Arora Arvind,Falk Stephen,Gillmore Roopinder,Wadsley Jonathan,Patel Kinnari,Anthoney Alan,Maraveyas Anthony,Iveson Tim,Waters Justin S,Hobbs Claire,Barber Safia,Ryder W David,Ramage John,Davies Linda M,Bridgewater John A,Valle Juan W
Funder
Stand Up To Cancer
Cancer Research UK
Cholangiocarcinoma Foundation
Reference40 articles.
1. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Valle;Ann Oncol,2016
2. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer;Valle;N Engl J Med,2010
3. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial;Shroff;JAMA Oncol,2019
4. Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer;Sakai;Ann Oncol,2018
5. Modified FOLFIRINOX versus CISGEM as first-line chemotherapy for advanced biliary tract cancer: results of AMEBICA PRODIGE 38 randomized phase II trial;Phelip;Ann Oncol,2020
Cited by
476 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献